Develops drug-eluting biomatrix products for surgical reconstruction.
Jun 2026Revenue $12.1M/yrExpenses $38.2M/yr
No trendCash runway ≈ 5 months from Jun 2026
Figures by year
When will Elutia be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $12.1M and expenses $38.2M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $12.3M | $39.2M | −$26.9M |
| Dec 2024 | $14.5M | $45.2M | −$30.7M |
| Dec 2023 | $24.7M | $55.3M | −$30.5M |
| Dec 2022 | $23.8M | $59.0M | −$35.2M |
| Dec 2021 | $47.4M | $70.4M | −$23.0M |
| Dec 2020 | $42.7M | $56.3M | −$13.6M |
| Dec 2019 | $42.9M | $51.3M | −$8.41M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.